Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
Open Access
- 22 May 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-8
Abstract
Background: The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects the gut microbiota in humans with non-haematological malignancy, independent of antibiotic exposure, is unknown. Methods: Faecal samples from 19 participants with non-haematological malignancy, who were receiving conventional chemotherapy regimens but not antibiotics, were examined prior to chemotherapy, 7–12 days after chemotherapy, and at the end of the first cycle of treatment. Gut microbiota diversity and composition was determined by 16S rRNA gene amplicon sequencing. Results: Compared to pre-chemotherapy samples, samples collected 7–12 days following chemotherapy exhibited increased richness (mean 120 observed species ± SD 38 vs 134 ± 40; p = 0.007) and diversity (Shannon diversity: mean 6.4 ± 0.43 vs 6.6 ± 0.41; p = 0.02). Composition was significantly altered, with a significant decrease in the relative abundance of gram-positive bacteria in the phylum Firmicutes (pre-chemotherapy median relative abundance [IQR] 0.78 [0.11] vs 0.75 [0.11]; p = 0.003), and an increase in the relative abundance of gram-negative bacteria (Bacteroidetes: median [IQR] 0.16 [0.13] vs 0.21 [0.13]; p = 0.01 and Proteobacteria: 0.015 [0.018] vs 0.03 [0.03]; p = 0.02). Differences in microbiota characteristics from baseline were no longer significant at the end of the chemotherapy cycle. Conclusions: Conventional chemotherapy results in significant changes in gut microbiota characteristics during the period of predicted myelosuppression post-chemotherapy. Further study is indicated to link microbiome changes during chemotherapy to clinical outcomes.Keywords
Funding Information
- South Australian Health and Medical Research Institute
This publication has 25 references indexed in Scilit:
- The microbiome, cancer, and cancer therapyNature Medicine, 2019
- Extensive impact of non-antibiotic drugs on human gut bacteriaNature, 2018
- Impact of the Microbiota on Bacterial Infections during Cancer TreatmentTrends in Microbiology, 2017
- Chemotherapy‐driven dysbiosis in the intestinal microbiomeAlimentary Pharmacology & Therapeutics, 2015
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCR-DGGE FingerprintingPLOS ONE, 2011
- Chemotherapy Treatment in Pediatric Patients with Acute Myeloid Leukemia Receiving Antimicrobial Prophylaxis Leads to a Relative Increase of Colonization with Potentially Pathogenic Bacteria in the GutClinical Infectious Diseases, 2009
- The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA SequencingPLOS Biology, 2008
- Toxicity, mutagenicity and drug resistance in Escherichia coli treated with platinum antitumor compoundsInorganica Chimica Acta, 1987